What is Idhifa used to treat?

Idhifa (enasidenib), from Celgene Corporation, is used to treat adult patients with relapsed (has returned after initial treatment) or refractory (has not responded to treatment) acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. IDH2 gene mutations may lead to immature blood cells becoming cancerous and dividing uncontrollably, causing AML.